Entities

Cross-border technology investor and Chip One Stop founder supporting Matter’s investment activities and industrial relationships in Japan.

Leads Rebellions’ global commercial growth and US expansion; previously led customer and commercial functions at SambaNova and held senior roles at Oracle.

Neurologist and physical therapist researching gait, mobility and falls in multiple sclerosis.

Natalia Korenev is published by Matter Venture Partners as Executive Admin, Investment Team.

Pragna Paranji is published by Matter Venture Partners as Chief of Staff.

Prem Jonnalagadda serves as Vice President, Marketing & Business Development at Delos Data.

Rachel Everman serves as Chief of Staff at Delos Data.

Neurologist researching progressive multiple sclerosis and leading veterans’ MS care.

Also known as Gina Kline; investor and former civil-rights lawyer focused on inclusive disability technology.

Savaughn Christman is published by Matter Venture Partners as Executive Admin, Operations & Platform.

Sherry Tsai is published by Matter Venture Partners as Taiwan Representative.

Rebellions co-founder and CEO, with a background in AI and system semiconductor engineering and a doctorate from MIT.

Tara Arvedson, PhD, is Chief Scientific Officer at Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome.

Tetsuya Umeki is published by Matter Venture Partners as Japan Advisor.

Zachary Cefaratti is published by Matter Venture Partners as Operating Partner & Head of Middle East.

Amanda White is listed by Ascension Investment Management, LLC as Chief Compliance Officer & Associate General Counsel. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Erin Carnes is listed by Ascension Investment Management, LLC as Senior Investor Relations Associate. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jessica Cook is listed by Ascension Investment Management, LLC as Managing Director of Business Development. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred. The2024 RCRI speaker biography says she leads business development and client relationships, joined AIM in2012, previously worked at Stark Investments and Strong Capital Management, and earned a finance degree at the University of Wisconsin–La Crosse.

Jill Barlow is listed by Ascension Investment Management, LLC as Senior Executive Assistant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Kayla Zalis is listed by Ascension Investment Management, LLC as Associate Director of Investor Relations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Nakeeta Miller is listed by Ascension Investment Management, LLC as Senior Executive Assistant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Todd Turall is listed by Ascension Investment Management, LLC as General Counsel & Chief Operating Officer. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Alex Poynter is listed by Ascension Investment Management, LLC as Senior Investment Analyst. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Cherie Browning Baur is listed by Ascension Investment Management, LLC as Accountant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jacob Styve is listed by Ascension Investment Management, LLC as Senior Accountant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jonathan Gierich is listed by Ascension Investment Management, LLC as Director of Finance & Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Mark Duncan is listed by Ascension Investment Management, LLC as Associate Director of Performance. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Matthew Goessling is listed by Ascension Investment Management, LLC as Senior Director of Finance & Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Melinda Beuttel is listed by Ascension Investment Management, LLC as Senior Accountant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Nathan Johns is listed by Ascension Investment Management, LLC as Senior Associate of Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Timothy McDowell is listed by Ascension Investment Management, LLC as Managing Director of Finance & Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Zachary Rasure is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Abhishek Rane is listed by Ascension Investment Management, LLC as Associate Director of Strategy & Risk Management. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jingwan Chen is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred. A legacy firm biography reports joining AIM in2015, previous investment roles at Edward Jones and T Rowe Price, a mathematics/economics degree from Kenyon College, and CFA/CAIA credentials.

Joshua Kaplan is listed by Ascension Investment Management, LLC as Managing Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Maurice Perry is listed by Ascension Investment Management, LLC as Managing Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Michael LeVar is listed by Ascension Investment Management, LLC as Managing Director of Strategy & Manager Research. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Scott Schleiffarth is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Tyler Blickhan is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Vincent Stegman is listed by Ascension Investment Management, LLC as Managing Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

David Erickson is listed by Ascension Investment Management, LLC as Chief Investment Officer. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred. He joined the Ascension investment office in2009 and previously served as CIO of the University of Wisconsin Foundation. His FOCUS St Louis biography reports an economics degree from Wheaton College and CFA credential.

Michael Griswold is listed by Ascension Investment Management, LLC as Deputy Chief Investment Officer. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Kimberly Reed is a Takeda external director and Audit and Supervisory Committee member. Her experience includes leadership of the US Export-Import Bank, the Community Development Financial Institutions Fund and public-policy and finance roles at the US Treasury and other organizations.

Bruce Broussard joined Takeda’s board and Audit and Supervisory Committee in June 2026. His leadership experience includes Humana, US Oncology and McKesson. Takeda’s published biography also lists his interim CEO role at HP beginning in February 2026.

Koichiro Kimura is a Takeda external director and head of its Audit and Supervisory Committee. His background includes representative executive leadership at PricewaterhouseCoopers Aarata, now PricewaterhouseCoopers Japan.

Miki Tsusaka joined Takeda’s board as an external director in June 2023. She has served as Microsoft Japan President since February 2023 and previously held senior partner, marketing and executive-committee leadership roles at Boston Consulting Group.

Paul Stoffels is a Takeda external director with pharmaceutical research and development leadership experience. His career includes leading pharmaceutical R&D and serving as vice chair and chief scientific officer at Johnson & Johnson.

Masami Iijima is a Takeda external director and chair of its board meeting. He has chaired the board meeting since June 2022. His career includes senior executive and representative-director leadership at Mitsui & Co.

Teresa Bitetti leads Takeda’s Global Oncology Business Unit, overseeing its international cancer medicines portfolio and commercial operations. She holds an MBA from the University of Virginia’s Darden School and a degree from Wellesley College.

Rhonda Pacheco leads Takeda’s US Business Unit and serves as US Country Head. Her portfolio spans gastroenterology, neuroscience, plasma-derived therapies and rare diseases. She holds a Duke Fuqua MBA and Doctor of Pharmacy degree from the University of Rhode Island.

Ramy Riad leads Takeda’s Plasma-Derived Therapies Business Unit. He holds an MBA in finance from Southern New Hampshire University and an accounting and business-administration degree from Cairo University.

Nicola Greenway is Takeda Chief Human Resources Officer, leading its global people function. Her qualifications include science degrees, business and management studies, employment law at the University of Surrey and an executive MBA from ENPC Paris and the University of Edinburgh.

Natalie Furney joined Takeda as Global General Counsel in April 2025. Her professional work includes legal leadership, continuous improvement and talent development, and she has participated in international trade-sanctions compliance forums.

Lauren Duprey is Takeda Chief Transformation Officer, responsible for connecting transformation initiatives across the company, including artificial intelligence programs. She holds a biology degree from Harvard University and an MBA from MIT Sloan.

Marcello Agosti is Takeda’s interim head of strategy and portfolio development. He leads business development, mergers and acquisitions and corporate development. He holds an Oxford MBA and a business-administration degree from Bocconi University.

Milano Furuta serves as Takeda Chief Financial Officer and a board director. He holds a Wharton MBA and a degree in international affairs from Hitotsubashi University in Japan.

Giles Platford leads Takeda’s International Business Unit, overseeing markets outside the United States. He focuses on commercial portfolio growth and international operations and is based in Tokyo. He holds a business and marketing-management degree from Oxford Brookes University.

Jennifer Smoter leads Takeda’s communications and governance organization, including corporate communications, brand, sustainability and coordination with its board. Her remit includes CEO chief-of-staff responsibilities and company reputation and stakeholder engagement. She is based in Boston.

Gabriele Ricci is Takeda Chief Data and Technology Officer, appointed in February 2022. He leads its data, digital and technology transformation. He holds an MBA from MIB Trieste School of Management and an engineering degree from the University of Rome Tor Vergata.

Elaine Shannon leads Takeda’s global supply and quality organization, covering internal and partner manufacturing, supply-chain operations and product quality. She holds a master’s degree in pharmaceutical manufacturing technology and an undergraduate qualification in good manufacturing practices.

Awny Farajallah is Takeda Chief Medical Officer. He joined in July 2021 as head of global oncology medical affairs and brings experience in clinical research, development and medical affairs. He earned his MD at Cairo University and undertook internal-medicine and infectious-disease training in the United States.

Andrew Plump leads research and development at Takeda and serves on its board. His training combines clinical medicine and cardiovascular genetics. He holds an MIT undergraduate degree, UCSF MD and Rockefeller University PhD, with residency and medical-genetics fellowship training at UCSF.

Asuka Miyabashira leads Takeda’s Japan Pharma Business Unit and serves as Japan Country Head. She joined in 2004 and has held marketing, medical and commercial leadership positions in Japan and internationally, including serving as country manager in Vietnam.

Julie Kim became Takeda President, CEO and Representative Director on 24 June 2026. She joined through the Shire acquisition in 2019 and previously led the plasma-derived therapies and US business units. Earlier experience includes Baxter, Baxalta and Shire. She holds a Kellogg MBA and Dartmouth economics degree.

Japanese public biopharmaceutical parent company founded as Chobei Takeda’s Osaka medicine business in 1781 and incorporated in 1925. Takeda has its global headquarters in Tokyo and a global research and business hub in Cambridge, Massachusetts, and manufacturing and research operations in Osaka. Its research and commercial work spans gastrointestinal and inflammatory diseases, neuroscience, oncology, plasma-derived therapies and vaccines. It integrates data, digital technologies and artificial intelligence into discovery and operations, including work with MIT. Its neuroscience business includes orexin-pathway research: the FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1 on 5 August 2026; approval and subsequent launch or controlled-substance scheduling are distinct. Julie Kim became President and CEO on 24 June 2026. The current public directory lists 16 executives and 11 directors, comprising 24 distinct people. This profile represents the parent corporation and its direct equity investments, including the historical $60M Wave Life Sciences subscription closed in April 2018, separately from commercial collaboration payments and the independently tracked Takeda Ventures entities.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Lead Independent Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Pfizer board director and founder and managing partner of GenNx360 Capital Partners. Previously founded Blaylock & Company and held senior investment-banking positions at UBS, PaineWebber and Citicorp. His Pfizer role is board oversight, separate from management or personal investments.

Chief Global Supply and Quality Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief People Experience Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief U.S. Commercial Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief Legal Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Head of Strategy, Executive Operations, Counsel to the CEO at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief International Commercial Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief Information Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Interim CFO and Executive Vice President of Pfizer, effective August16,2026. Previously senior vice president of finance for its Global Biopharmaceuticals business. Has more than25years in global pharmaceutical finance. Pfizer’s June2026SECfiling states she joinedPfizerin2005; the websitebiography associates her arrival with the2009Wyethacquisition, so the SECemployment chronology is used for that detail.

Chief Scientific Officer and President, Research & Development of Pfizer, directing research across therapeutic areas and its business-development organization. Previously Chief Oncology Officer and founding director of the UCL Cancer Institute; trained as a medical oncologist.

Chairman and CEO of Pfizer. Became CEO in January2019. Veterinary medicine doctorate and biotechnology-of-reproduction PhD from Aristotle University. Current primary biography describes AI as central to Pfizer medicine discovery, development and manufacturing.

Pfizer Inc. is a global biopharmaceutical operating company founded in1849 by Charles Pfizer and Charles Erhart, headquartered in New York City and listed on the NYSE as PFE. It discovers, develops, manufactures and commercializes medicines and vaccines across oncology, internal medicine, inflammation and immunology, and vaccines. AI supports its medicine discovery, development and manufacturing; primary examples include molecular design, predictive biomedical-data analysis and quantum-physics-assisted crystal-structure prediction. Its relevance to neuroscience includes neurological and migraine medicines and historical genetics-focused research partnerships; its Wave Life Sciences equity investment supported stereopure oligonucleotide programs. The parent company is distinct from Pfizer Ventures. Pfizer agreed to a $30million Wave equity purchase in May2016 through affiliate C.P. Pharmaceuticals International C.V.; this was part of a $40million upfront collaboration payment, with the remaining $10million a commercial payment. Current public leadership lists10executives and12boardmembers, with Albert Bourla in both groups. Pfizer first offered shares to the public on June22,1942.

Brooke Thurston is Chief of Staff and Head of Communications and Policy at Morgan Health. She previously held chief-of-staff and communications responsibilities at Haven, the JPMorganChase, Amazon and Berkshire Hathaway joint venture, and worked on Capitol Hill and at VOX Global. She holds a government degree from Colby College.

Joe Tobias is Chief Financial Officer for Corporate Responsibility and Morgan Health at JPMorganChase, with additional oversight of the American Dream Initiative. He has held financial-control, risk-reporting and sustainability-reporting roles across more than eighteen years at JPMorganChase and is treasurer and board member of its Foundation. He holds a finance degree from Pennsylvania State University.

Jeffrey Ries, also published as Jeff Ries, is Partner and Co-Head of Investments at Morgan Health. His official current biography lists board service at Fuze Health and Thyme Care. He previously led venture investing at Healthbox, including the DaVita Venture Fund and Intermountain Health Care Innovation Fund, and worked at Oxeon Partners, Sandbox Industries and LaSalle Investment Management. He holds degrees from Northwestern and Harvard Business School.

Dan Mendelson is CEO of Morgan Health. He founded and led Avalere Health and previously served as Associate Director for Health at the Clinton administration’s Office of Management and Budget. His current official biography lists board service at Champions Oncology and the Peterson Center on Healthcare and adjunct teaching at Georgetown McDonough. He holds degrees from Oberlin and Harvard Kennedy School.

Trey Hollern is Executive Director and Head of External Communications at Morgan Health. His prior communications roles included Becton Dickinson, CVS Health Caremark, APCO Worldwide and Porter Novelli. He holds journalism and integrated-marketing-communications degrees from West Virginia University.

Dan Hartman is Partner and Co-Head of Investments at Morgan Health. His current official biography identifies board service at Centivo and Cortica. He previously led analytics and transformation at Beacon Health Options, advised clients at Boston Consulting Group, and worked in healthcare investment banking at Goldman Sachs. He served seven years in US Army Special Forces and holds bachelor’s and master’s degrees from Georgetown. This is the healthcare investor, rather than the similarly named medical-research executive.

Katie Bobroske leads Morgan Health’s Data Science and Research team, developing healthcare data-warehouse insights for JPMorganChase’s health plan and the employer-insurance market, supporting investment diligence and portfolio companies, and engaging on healthcare data and AI policy. Earlier roles included McKesson, Evolent Health, the UK National Health Service and Haven. She earned a PhD and MPhil at Cambridge Judge Business School and an operations-research degree at Cornell.

Morgan Health is JPMorganChase’s healthcare investment and innovation business unit, rather than a standalone incorporated fund manager. Its current site identifies the legal parent as JPMorgan Chase Bank, NA. Led by CEO Dan Mendelson, the Washington, D.C.-headquartered unit works to improve the quality, affordability and equity of US employer-sponsored healthcare through balance-sheet investments, data science, accountable-care initiatives and evaluation of health benefits. Its focus spans primary care and navigation, data analytics, new coverage options, specialty and at-home care, and pharmacy. Its neuroscience-related investments include Cortica, a provider of integrated medical and developmental care for autistic and neurodivergent children; its data-science team also works on healthcare data and AI policy and supports investment diligence. The current portfolio directory lists twelve companies, including Cortica, Thyme Care, Centivo, Devoted, Aradigm, Merative, Personify Health, Mosaic Health, Quantum Health, Kindbody, Fuze Health and Lantern. Morgan Health launched in May 2021 with authorization to invest up to $250M of JPMorganChase capital. This allocation is not an externally raised fund, a final fund close or current assets under management. On November 20, 2024, Morgan Health co-led Cortica’s actual $80M financing with Nexus NeuroTech Ventures; the unit’s individual investment amount was undisclosed. The InvestmentFirm classification here identifies the corporate investment platform and does not imply separate legal incorporation.

A. James Khodabakhsh, MD, is a director of Amydis. An ophthalmic surgeon, he specializes in cataract, glaucoma and refractive procedures and has worked in clinical leadership and surgical-center management in Beverly Hills.

Jerre Stead is a director of Amydis and founder and chairman of Stead Impact Ventures. He formerly led Clarivate and IHS Markit and has served as CEO or chairman of numerous public companies; his philanthropic work includes Alzheimer's research. Jerre Stead serves on Spinogenix’s board and chairs Stead Impact Ventures. His earlier business leadership includes Clarivate and IHS Markit, alongside philanthropic support for research into Alzheimer’s disease. Jerre Stead is co-founder and board chair of ALZpath, a blood-based Alzheimer’s diagnostics company founded in2020.

Philip Werthman, MD, MMH, serves on Amydis' Scientific Advisory Board. A microsurgeon and biotech investor, he founded Merkava Holdings and has advised companies in biotechnology, pharmaceuticals and aerospace. His training includes neuropsychology, medicine and military history. He is Founder and President of Merkava Holdings, the investment arm of the Philip E. Werthman Trust, supporting early and mid-stage technology and life-sciences companies through investment and international business development.

Robert Zamboni, PhD, serves on Amydis' Scientific Advisory Board. A medicinal chemist with more than four decades in drug discovery, he worked on Singulair and other medicines at Merck Frosst and later founded drug-discovery consulting business ZCS.

Jeffrey Kordower, PhD, serves on Amydis' Scientific Advisory Board. His research specializes in Parkinson's disease, related neurodegenerative disorders and nonhuman-primate models. He helped establish the ASU-Banner Neurodegenerative Disease Research Center.

Jose Pulido, MD, MS, MBA, MPH, serves on Amydis' Scientific Advisory Board. His research spans vitreoretinal inflammation and infection, retinal degeneration, stem cells and immunotherapies; his career includes translational research at Mayo Clinic and Wills Eye Hospital.

Irene Litvan, MD, serves on Amydis' Scientific Advisory Board. Her expertise includes Parkinsonian disorders, cognitive neuroscience and epidemiology, including work to improve clinical diagnostic criteria for neurodegenerative movement disorders.

Eric M. Reiman, MD, serves on Amydis' Scientific Advisory Board. A psychiatrist and brain imaging researcher, he studies Alzheimer's biomarkers, APOE genetics and prevention and co-founded the Alzheimer's blood-test company ALZPath. Eric M. Reiman is ALZpath co-founder and scientific adviser, and founding CEO of Banner Alzheimer’s Institute. His research spans brain imaging, Alzheimer’s genetics, blood biomarkers and prevention.

SriniVas R. Sadda, MD, serves on Amydis' Scientific Advisory Board. His research applies automated image analysis and advanced retinal imaging to ophthalmology, drawing on neuro-ophthalmology and medical retina training at Johns Hopkins.

Steven D. Schwartz, MD, serves on Amydis' Scientific Advisory Board. His research concerns macular degeneration, retinopathy of prematurity, diabetic eye disease and the development of imaging, surgical and drug-delivery technologies.

Alex Huang, MD, PhD, is Chief Medical Advisor at Amydis and an ophthalmologist specializing in glaucoma and cataract surgery. His research addresses aqueous humor outflow, glaucoma surgical outcomes and ocular changes during spaceflight.

Alfredo Sadun, MD, PhD, serves on Amydis' Scientific Advisory Board. His work centers on neuro-ophthalmology and optic nerve disorders, with training at MIT and Harvard and a career in academic ophthalmology.

David S. Boyer, MD, serves on Amydis' Scientific Advisory Board. A retinal clinician and surgeon, he helped establish Retina-Vitreous Associates Medical Group in Los Angeles and has investigated retinal disease treatments in clinical trials.

Vicki P. Raeburn, PhD, is Chief Data Science Officer at Amydis. Her career includes leadership of analytical and information operations at IHS, Dun & Bradstreet, Mergent and other financial information businesses. She earned a doctorate in cognitive psychology at Yale University.

Kerri Nelson is Chief Operating Officer at Amydis. She has led data strategy, products, customer operations and integration at Dun & Bradstreet, IHS Markit and Clarivate, and founded customer-experience analytics company CustomersFirst Now.

Clinical-stage biotechnology company developing small-molecule fluorescent ocular tracers to detect disease-related proteins through standard eye imaging. Its research targets amyloid beta, alpha-synuclein, tau, TDP-43 and other molecular biomarkers linked to neurodegenerative, ophthalmic and cardiovascular disorders. Amydis combines tracer chemistry, retinal imaging and AI-based analysis of molecular biomarker patterns, including a 2026 NIH-supported TDP-43 program for ALS, frontotemporal dementia and LATE. Its diagnostic candidates remain investigational; human clinical studies do not establish an approved screening test or treatment for Alzheimer's disease or Parkinson's disease. Stella Sarraf founded Amydis in 2013. The company has corporate offices in Los Angeles and a laboratory in La Jolla and was previously named Amydis Diagnostics Inc. Its public funding includes NIH and Michael J. Fox Foundation research grants and three SEC-disclosed private securities offerings in 2022-2023. Grant budgets, offering targets and amounts actually sold are recorded separately.

Ali Tafreshi is Chief Technology Advisor at Amydis. His experience spans glaucoma, neuro-ophthalmology, retinal conditions and clinical trials, including research at the Hamilton Glaucoma Research Center and product management and clinical affairs at Heidelberg Engineering. Topcon Healthcare CEO, explicitly retained in the October 6, 2026 Oku launch announcement. Also CEO of the separately launched Oku Digital Health and global EyeCare chief strategy officer at parent Topcon Corporation. His former combined CEO/president title was superseded when Lance Patton became president in April 2026.

Stella Sarraf founded Amydis in 2013 and leads it as CEO and a director. She trained in organic chemistry at Columbia University and biochemistry and molecular biology at UC Berkeley. Her prior experience includes Merck chemistry and healthcare venture investing at Foresite Capital and Prospect Venture Partners; she also founded Spinogenix in 2016. Stella Sarraf founded Spinogenix in 2016 and serves as CEO and a director, alongside her leadership of Amydis. Her background combines medicinal chemistry, pharmaceutical operations, venture investment and company formation.

Abigail Cahak is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Legal Officer. The published directory describes this background: Abi joined the Wisconsin Foundation and Alumni Association’s legal affairs team in February 2019 and became chief legal officer in 2022. Prior to WFAA, she was with a large firm based in Chicago, where she practiced primarily in the areas of labor and employment counseling and litigation with clients across several industries.

Alice Mortenson is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: President & Chair, Mortenson Family Foundation Director of Community Relations M.A. Mortenson Company

Ana Maria Murphy is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Director of Investment Operations (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Brad Tank is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member; Investment Committee Member (WISIMCO investment division). The published directory describes this background: Senior Advisor, Neuberger Berman

Brenda Phebus is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Human Resources Officer. The published directory describes this background: Brenda joined the Wisconsin Foundation and Alumni Association as chief human resources officer in 2018. She has previously held multiple HR leadership positions in organizations spanning telecommunications, financial services, and small businesses.

Carl Laurino is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Financial Officer. The published directory describes this background: An experienced CFO with both public and private-equity-owned companies, Carl came to WFAA in January 2022. He earned his undergraduate degree at UW–Eau Claire and began his career in banking.

Chris Moore is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Deputy Chief Investment Officer (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Chris Salm is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Chief Executive Officer, Ab E Discovery

Christine Rotsch is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: President, Rotsch Family Foundation

Cynthia Ihlenfeld is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Artist and Mobilizer of Time, Talent, and Resources for Education and Arts Non-Profits

Dan Treuter is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Vice President, Digital Experience and Innovation. The published directory describes this background: Dan joined the Wisconsin Foundation and Alumni Association in 2006 and serves as vice president of digital experience and innovation. In this role, he leads WFAA’s digital strategy and enterprise-wide digital roadmap, overseeing the platforms and systems that support alumni and donor engagement, online giving, and marketing operations.

Dana Serwe is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Investment Office Chief of Staff (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

David Nicholas is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member; Investment Committee Member (WISIMCO investment division). The published directory describes this background: Chief Executive Officer, President, Chief Investment Officer and Portfolio Manager, Nicholas Funds

David Rosenberg is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Co-Founder and chief Executive Officer, Lucid Capital Markets, LLC

Debbie Cervenka is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Retired Executive Vice President, Phillips Plastics Corporation

Elizabeth Quadracci Harned is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: President of The Winderful Foundation Trustee, Quad Graphics, Inc.

Elzie Higginbottom is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: President & CEO, East Lake Management & Development Corporation

Erik Iverson is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Investment Committee Advisory Member (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Fran Taylor is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Ex-Officio Board Member. The published directory describes this background: Retired Executive Vice President, Bank of America Corporation

Frank Ace is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Vice President, Information Technology. The published directory describes this background: Frank joined the UW Foundation in 2013 as director of IT. He received his bachelor’s degree in computer sciences from UW–Madison and has worked in the IT field for more than 30 years.

Garrett Gardner is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Director of Investment Operations (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Greg Elkins is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Managing Director of Investments (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Greg Sinaiko is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Owner and Principal, 10 West Partners, Inc.

Jeffrey Wiesner is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Ex-Officio Board Member. The published directory describes this background: Retired Partner, Accenture

Jere Fluno is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Ex-Officio Board Member. The published directory describes this background: Retired Vice Chairman & Director, WW Grainger, Inc.

Jim Kennedy is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Marketing and Communications Officer. The published directory describes this background: Jim joined the Wisconsin Foundation and Alumni Association in 2014. He leads the marketing and communications division, where he oversees brand management, digital experience and engagement, alumni communications and publications, and annual giving programs.

Jim Thompson is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Former President, Cargill Steel

John Oros is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Ex-Officio Board Member; Investment Committee Member (WISIMCO investment division). The published directory describes this background: Operating Partner, Managing Director & Management Committee, JC Flowers & Co.

Jun Lee is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Retired President, SRI Design, Inc.

Katherine Wyble is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Managing Director of Investments (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Kyle Buchmann is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Senior Vice President of Development. The published directory describes this background: Kyle Buchmann joined the Wisconsin Foundation and Alumni Association as director of development for corporate and foundation relations in 2012. From 2018 to 2024, he led the College of Engineering development team before being promoted to senior vice president in 2024.

Linda Ahlers is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Retired President, Marshall Field’s

Lorna Nagler is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Retired President, Bealls, Inc.

Louis Holland is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chair of the Board; Investment Committee Member (WISIMCO investment division). The published directory describes this background: President & CFO, Cumota, LLC

Marianne Siess is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Information Officer. The published directory describes this background: Marianne joined the staff of the UW Foundation in 2008 as a member of the prospect research team. She took on her current position in 2019, overseeing the research and prospect management team as well as constituent data processing, records management, data solutions, advancement business solutions, and gift processing.

Michael Ferdman is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Co-Founder, Play

Michael Knetter is an Investment Committee Advisory Member of the University of Wisconsin Foundation’s WISIMCO investment division and serves as a senior adviser on the investment team. He previously served as WFAA president and CEO from 2010 through 2024; Alisa Robertson became CEO in January 2025.

Michael Shannon is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member; Investment Committee Member (WISIMCO investment division). The published directory describes this background: Former Chairman, Co-Founder, & CEO KSL Capital Partners LLC

Michael Stohler is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Investment Officer; Chief Investment Officer (WISIMCO investment division). The published directory describes this background: Michael became WISIMCO’s chief investment officer in 2021. Prior to that, he was a managing director of investments at Washington University in St.

Michele Bernius is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Director of Investments (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Patty Shinners is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Retired Nurse Practitioner

Paul Collins is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Ex-Officio Board Member. The published directory describes this background: Retired Vice Chair, Citigroup

Paul Leff is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Investment Committee Advisory Member (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Paul Shain is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: President & CEO, Singlewire Software

Rachel Lionberg is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Senior Vice President of Development. The published directory describes this background: Rachel Lionberg is an accomplished advancement professional with more than two decades of experiences in higher education development. She joined the Wisconsin Foundation and Alumni Association in 2016 as associate vice president and managing director for the Wisconsin School of Business and was promoted to Senior Vice President in 2024.

Rajiv Batra is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Co-Founder, Palo Alto Networks

Richard Shepley is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Senior Managing Director of Investments (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Roger Mansukhani is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Partner at Gordon Rees Scully Mansukhani

Samir Murty is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Principal and Senior Relationship Manager, Orgel Wealth Management

Sandy Sponem is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Retired Senior Vice President & CFO M. A.

Sarah Schutt is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Alumni Engagement Officer and Executive Director, Wisconsin Alumni Association. The published directory describes this background: Sarah joined the Wisconsin Alumni Association (WAA) in August 2001, initially as the director of alumni lifelong learning. Between April 2009 and December 2010, she worked at the UW’s Division of Continuing Studies before returning to WAA.

Sean Arp is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Chief Operating Officer of Investments (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Sonnet Edmonds is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: General Counsel, Dimension Renewable Energy

Stephen Petersen is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Investment Committee Advisory Member (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Susan Patterson is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Former SVP, J. Walter Thompson NY (advertising)

Suzanne DeWolf is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: Co-Owner, Lil’ Drug Store Products Co-Owner, ForeFold Ventures

Ted Kellner is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Ex-Officio Board Member; Investment Committee Member (WISIMCO investment division). The published directory describes this background: Founder, Chairman & CEO, Fiduciary Management

Thomas Stevens is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member; Investment Committee Chair (WISIMCO investment division). The published directory describes this background: Chair & CEO, Los Angeles Capital

Todd Pulvino is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Vice Chair of the Board; Investment Committee Member (WISIMCO investment division). The published directory describes this background: Principal and Co-Founder, CNH Partners

Travis Ace is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Director of Investment Operations (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Valarie King-Bailey is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Board Member. The published directory describes this background: CEO, OnShore Technology Group, Inc

Private, independent nonprofit fundraising and financial partner of the University of Wisconsin–Madison, established in 1945. The University of Wisconsin Foundation receives philanthropic gifts and manages and distributes gift and investment income for scholarships, campus facilities, research and other university priorities. In 2014 it merged with the Wisconsin Alumni Association to form the Wisconsin Foundation and Alumni Association (WFAA); the UW Foundation and alumni association are its divisions. Wisconsin Investment Management Company (WISIMCO) is the operational name of the Foundation’s investment division, overseeing its endowment investment portfolio and affiliated capital, rather than a separately identified venture fund. The Foundation is an explicitly named investor in Cortica’s October 2023 Series D extension, connecting it to neuroscience-informed care for autism and other neurodevelopmental conditions. Its published leadership, board and investment committee govern philanthropic and investment stewardship; University faculty and WARF personnel are not presumed to be employees. The University, Wisconsin Alumni Research Foundation (WARF), UW System Trust Funds and UW Medical Foundation are separate organizations.

Alisa Robertson is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: President and Chief Executive Officer. The published directory describes this background: Alisa is president and CEO of the Wisconsin Foundation and Alumni Association, a role she assumed on January 1, 2025. Previously she served as the organization’s president and chief advancement officer, with more than 20 years of experience in nonprofit leadership, fundraising, and stakeholder engagement.

Ascension Investment Management, LLC (AIM) is a St. Louis, Missouri-based SEC-registered investment adviser serving faith-based institutional investors under Catholic socially responsible investment guidelines. The Missouri LLC is wholly owned by Ascension Capital, LLC, which is wholly owned by nonprofit Catholic healthcare system Ascension. Its internal investment-office roots date to2009; it registered as an adviser and expanded services to outside institutions in2012. AIM provides outsourced CIO and selected-asset-class investment management across public markets, alternatives and private markets, including healthcare, climate and other impact investments. Its relevance to neuroscience includes its explicitly named participation in Cortica’s actual $40 million Series D extension in October2023, supporting autism and neurodevelopment care. AIM is distinct from both Ascension Ventures and the UK investor at ascension.vc. The current website publishes27 named team members and reports $40 billion of client assets under management for2025; this AUM is not a closed venture fund. Its earlier impact-program allocations are client strategy commitments, while actual named fund vehicles include Ascension Alpha Fund, LLC and the jointly developed Common Good Fund, whose first close was announced in August2026 with size undisclosed.

Clene director and Managing Director and CEO of Kensington Capital Holdings, a US single-family office. Her background includes private wealth, accounting and family office work at Audax and PwC.

Clene director and neurologist researching ALS, motor neuron disease and frontotemporal dementia. CEO and Institute Director of Neuroscience Research Australia.

Clene Nanomedicine co-founder and director, with technology invention and business strategy experience. Former president of Southern Virginia University, now president emeritus.

Clene director and University of Michigan cardiology professor who leads its pulmonary hypertension program, with extensive clinical trial experience.

Clene independent director and physician with experience in focused ultrasound and neuroscience innovation. Clene’s current biography identifies him as CEO of Lotus Neuro, formed from Insightec. Arjun JJ Desai is listed in Despierta’s combined advisors/select-LPs roster. Its biography describes earlier Insightec innovation leadership, Johnson & Johnson JLABS operating work and Stanford medical/biodesign involvement. This is the same physician as the existing ArjunJJDesai; that existing newer Lotus Neuro/Clene biography is preserved rather than replaced by older credentials.

Clene board chairman sinceMay2021 and director sinceDecember2020. Co-founded MatlinPatterson and formerly served as its CEO; has medical device, biotechnology and public company board experience.

Clene director and Managing Partner of Kensington-SV Global Innovations, co-founded in2018. Previously led investments at Kensington Capital Ventures and worked at HGGC.

Clene director since2013 and former chairman throughMay2021, with pharmaceutical and healthcare association leadership experience at Actelion, Idorsia and the American College of Cardiology.

Clene Director of Micro and Biology and a physician-scientist experienced in microbiology and preclinical neuroscience. Helped investigate CNM-Au8 remyelination and neuroprotection in experimental MS and ALS models.

Clene Executive Director of Quality Assurance, with regulated pharmaceutical and clinical manufacturing experience at Johns Hopkins and Meridian BioGroup.

Clene Vice President of Research and Development, involved in developing nanocrystal production equipment, software and manufacturing processes since the company’s inception.

Clene Vice President of Clinical Operations with CNS and pain clinical research experience, including study design and management across early and later clinical phases.

Clene Vice President of Quality and Technical Operations, with experience in nanoparticle characterization, clinical specimen bioanalysis and quality systems. Joined Clene in2013.

Clene General Counsel and Corporate Secretary, with experience in corporate transactions and legal leadership at Jabil and Miles & Stockbridge.

Head of Human Resources at Clene, leading workforce development, management training and organizational culture.

Clene Chief Development Officer with experience in regulatory submissions, translational development and commercialization. Previously a founding US team member at Actelion.

Clene Chief Financial Officer and Utah certified public accountant, with finance leadership experience at Lipocine, Innovus Pharmaceuticals, World Heart and NPS Pharmaceuticals.

Clene Chief Science Officer and co-inventor of its clean-surface nanocrystal platform. His background spans physics, ceramic and materials engineering, patent law and technology manufacturing.

Clene founding CEO and President, previously a founding commercial leader at Actelion with pharmaceutical sales and marketing experience. His legal name in SEC filings is Robert Etherington.

Clene Inc. (Nasdaq: CLNN) is a clinical-stage neuroscience and nanomedicine company developing catalytically active gold nanocrystals to improve cellular energy metabolism and neuronal function. Its wholly owned Clene Nanomedicine subsidiary develops CNM-Au8, an investigational oral suspension studied in ALS, multiple sclerosis and Parkinson’s disease. As of the September 2026 issuer update, an ALS NDA under the accelerated approval pathway was planned; FDA acceptance and marketing approval had not been announced. A future confirmatory Phase 3 program remains planned, distinct from earlier completed clinical studies and expanded-access programs. The operating business was founded in 2013 and became publicly traded through its 2020 Tottenham SPAC combination. Headquarters are in Salt Lake City, with manufacturing and research in North East, Maryland. Current published leadership comprises 12 people and a nine-member board, with the CEO serving in both.

Rishi Malla is a pediatric neurologist and epilepsy specialist at Cortica with expertise in pediatric EEG interpretation. He studied at UC Berkeley, Georgetown and Texas A&M and completed pediatric-neurology training at the Medical University of South Carolina.

Stephen Posluszny practices pediatrics at Cortica. He studied at Notre Dame and Cincinnati, trained at Rainbow Babies and Children’s Hospital and previously provided outpatient pediatric care in Ohio and New Jersey.

Regina Troxell is a pediatric neurologist and area medical director at Cortica with experience caring for autistic children. She trained at St George’s and UTHealth Houston and has supported mentoring for women neurologists and programs for young people with demyelinating disorders.

Jennifer Hanson is a pediatrician at Cortica whose work emphasizes family participation in care. She studied molecular biology at UC Berkeley, medicine at Drexel and pediatrics at UC Irvine, followed by a decade in private practice.

Jainy Vathikulam is a pediatric neurologist at Cortica focused on neurodevelopmental disabilities. She earned an osteopathic medical degree at Midwestern University and trained in pediatrics and child neurology at Loma Linda.

Margalit Kochav is a pediatrician at Cortica serving children in Ventura and Los Angeles counties. Her training includes neurobiology at UC Irvine, medicine at Ross University and pediatric residency at the University of Nevada in Las Vegas.

Mark Barros practices general pediatrics at Cortica, evaluating neurodevelopmental conditions including autism, ADHD and associated sleep, genetic and metabolic disorders. He trained in medicine at UTHealth Houston and in pediatrics at Penn State Hershey.

Juliana Ndidi Anyanwu is a pediatrician at Cortica with experience in clinical care and public-health research. She trained at Michigan and Cincinnati Children’s, following degrees from Dillard and Tulane, and previously worked at Cambridge Health Alliance.

Hitha Amin is a pediatric neurologist at Cortica with training in neurodevelopmental conditions, neurogenetics and neurometabolic disorders. She previously practiced general pediatrics in Marin County and completed specialist training at Baylor College of Medicine.

Gaurav Yadava is a pediatric neurologist, area medical director and national head of medical practice management at Cortica. His training includes Saint Louis University and pediatric and child-neurology residencies in Chicago, with qualifications in child neurology and epilepsy.

Gwenn O’Keeffe is a pediatrician at Cortica whose work includes child health, advocacy, digital media and family conflict resolution. She trained at Tufts and Boston Floating Hospital and also holds a law degree.

Haley Masterson is a site medical director and pediatric neurologist at Cortica, focused on autism and neurodevelopment. She trained at Columbia and Cleveland Clinic and previously practiced pediatric neurology in Iowa.

Beth Johnson is a neurodevelopmental pediatrician at Cortica, supporting children with developmental conditions and their families. She previously practiced pediatrics at Grand Forks Air Force Base and emphasizes coordinated diagnosis, treatment and family support.

d-Matrix develops specialized computing hardware, networking and software for low-latency generative AI inference in data centers. Its digital in-memory compute architecture brings processing closer to memory to address the bandwidth bottlenecks of large language models, aiming to lower power consumption and operating costs. Its platform combines Corsair inference accelerators, JetStream networking and Aviator software, with a 3D-stacked-memory Raptor accelerator in development. Founded in 2019 by Sid Sheth and Sudeep Bhoja, the company is headquartered in Santa Clara and serves enterprise, hyperscale and sovereign AI infrastructure customers.

Muna Therapeutics develops oral small-molecule medicines intended to preserve brain function in neurodegenerative diseases. Its MiND-MAP discovery platform uses spatial single-cell multi-omics and bioinformatics from human patient tissue to identify mechanisms of resilience to Alzheimer’s, Parkinson’s and other disorders, supported by structural biology and computational chemistry. Lead TREM2 agonist MNA-001 is in Phase 1 testing in healthy young and older adults to modulate microglial function for Alzheimer’s disease; a separate preclinical Kv1.3 blocker program targets neuroinflammation in Parkinson’s and multiple sclerosis.

NeuroXT develops artificial intelligence software that analyzes brain MRI scans and clinical information to support Alzheimer’s disease assessment and precision treatment research. Its NEXT-Cue product supports cognitive-decline assessment, NEXT-STAGE estimates regional tau burden from MRI for research, and NEXT-SCN studies synaptic integrity and responses to synapse-targeted therapies. The company collaborates with clinical research institutions to validate imaging biomarkers and predict individual treatment responses.

Phrontline Biopharma develops antibody-drug conjugates for cancer treatment. Its bispecific antibodies and dual-payload platforms aim to deliver cytotoxic medicines more precisely to tumors and address treatment resistance. Lead candidate TJ101 targets EGFR and B7-H3 and is in early clinical development; other programs include dual-payload candidates targeting HER2 and additional tumor antigens. Its research combines antibody engineering, linker-payload design and site-specific conjugation.

Alex LeBrun is a member of the founding team at AMI Labs, which researches world models for AI systems that understand and act in the physical world.

Andrew Gordon Wilson serves as a BigHat Biosciences advisor.

Executive assistant with prior experience across Sanofi digital, vaccines and business development teams.

Brandon Barbello serves as the Chief Operating Officer of Archetype AI. He has 13+ years of experience as a senior product leader shipping innovative hardware, software, and AI products at Google and startups in sensing and fintech. Most recently, he led privacy-preserving on-device AI projects at Google.

Brian Kobilka serves as a BigHat Biosciences advisor.

Christina Buchanan is publicly identified with NVentures as Principal. Emerald AI’s current company directory identifies her as Principal at NVIDIA NVentures and a board observer. The directory establishes this venture-unit affiliation without publishing an appointment date or further career details.

Cillian King, PhD, is a QurAlis director and an EQT Life Sciences investor associated with its LSP Dementia Fund. His earlier career includes Swanbridge Capital and neuroscience research, with training at VU Amsterdam and MIT.

Digital health and AI investor; previously led digital innovation at Johnson & Johnson and emerging research technology programs at Novartis.

Donald Nicholson, published by Atlas as Don Nicholson, is an Atlas adviser and former CEO of Nimbus Therapeutics. His own Atlas biography and Muna board biography describe 25 years at Merck and research into apoptotic cell death. He earned a biochemistry PhD at Western Ontario and completed postdoctoral training in Munich. The current Atlas card names an executive-chair role at Disc; company governance is separate from Atlas fund employment.

Machine learning researcher formerly principal machine learning engineer at Apple and senior staff software engineer at Google; holds a University of Illinois Urbana-Champaign computer engineering PhD.

Eileen (Ellie) McGuire is a Boston managing partner at Polaris and manages its Innovation Fund. The manager confirms her Muna Therapeutics and Noema Pharma board affiliations. Previously led business development at Lyndra and held life-sciences operating and advisory roles.

Early-stage biotechnology investor previously with AdBio Partners, Kiji Therapeutics and the University of Barcelona technology transfer office.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Ivan Poupyrev, Ph.D., is the Chief Executive Officer of Archetype AI, with 20+ years of experience in research and product development. An award-winning inventor, engineer and technical leader, he spearheaded technology development for Google’s ATAP, Walt Disney Imagineering, Sony, and others. Ivan holds an M.S. in Applied Mathematics and Computer Science from Moscow Airspace University and a Ph.D. in Computer Science from Hiroshima University.

Jacob Gardner serves as a BigHat Biosciences advisor.

Jaime Lien is the Chief Scientist at Archetype AI, with 12+ years of experience developing and productizing novel perceptual sensing systems. Prior to Archetype, Jaime was a Sensing Lead at Google’s Advanced Technology and Projects, inventing and shipping Soli radar in multiple consumer devices. She previously developed wireless communication and localization technologies at NASA’s Jet Propulsion Laboratory. Jaime received a B.S. and M.Eng. in Electrical Engineering from MIT and a Ph.D. in Electrical Engineering from Stanford University.

Javin Oza serves as a BigHat Biosciences advisor.

Marketing executive with prior work at Autodesk and OpenSpace; leads marketing and category development for Archetype AI.

John Tough co-founded Energize Capital and serves as managing partner, overseeing investing and limited-partner relationships. He participates in its management, Ventures and Endurance committees. He previously led operations and growth at Choose Energy as chief revenue officer and invested at Kleiner Perkins. His published board roles include Sitetracker, DroneDeploy, Nozomi Networks, Matroid, PVcase and Aurora Solar.

Neuroimaging AI researcher and NeuroXT CEO, also published in the company footer as Seong Joon Kyung. Leads development and commercialization of Alzheimer’s precision medicine imaging technologies and is affiliated with Korea University.

Healthcare services, digital-health and medical-technology investor formerly with RA Capital, trained in medical engineering and biomedical engineering.

Biotechnology investor and former Ysios Capital investment director, trained in chemistry and drug development.

Laurent Solly is a member of the founding team at AMI Labs, which researches world models for AI systems that understand and act in the physical world.

Lawren Wu serves as a BigHat Biosciences advisor.

Leonardo Giusti, Ph.D., is Archetype AI's Chief Design Officer with over 15 years of experience as an award-winning design and research director, excelling in transforming R&D projects into innovative hardware, software, and AI products. Prior to Archetype AI, Leonardo held key design roles at Google's Advanced Technology and Projects group and Samsung Design. He was a Postdoctoral Associate at MIT Design Lab and completed his Ph.D. in human-machine interaction at the University of Florence.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Luc Dochez is a QurAlis director and biotechnology investor associated with Droia. His published biography describes leadership at Tusk Therapeutics and Prosensa, earlier roles at TiGenix and Arthur D. Little, and pharmacy, economics and MBA training in Belgium. Luc Dochez is named Managing Partner Genetic Disease in Droia’s current public directory. The published professional background includes Pharm.D., University of Leuven; MBA, Vlerick Management School; Arthur D. Little; TiGenix; Prosensa; Tusk Therapeutics; Independent board member Erytech, Pharvaris. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Marc Martin-Casas serves as a BigHat Biosciences board member.

Mark DePristo co-founded BigHat Biosciences in 2019 and is now published by the company as an adviser; the current chief executive officer is co-founder Peyton Greenside.

Physician leading clinical development at Phrontline Biopharma, including investigational antibody-drug conjugates for solid tumors.

Biotechnology investor with a neuroscience doctorate and prior external-innovation and investing experience at Vertex and RA Capital.

Michael Jewett serves as a BigHat Biosciences advisor.

Michael Stewart is a Managing Partner at M12 and a board director at d-Matrix. His previous experience includes Applied Ventures, Applied Materials and Intel. His background includes semiconductor technology and a doctorate from Purdue.

Mike Rabbat is a member of the founding team at AMI Labs, which researches world models for AI systems that understand and act in the physical world.

Min Lin is a member of the founding team at AMI Labs, which researches world models for AI systems that understand and act in the physical world.

Archetype AI co-founder and CTO. Nick was a Postdoctoral Associate and Fulbright Scholar at the MIT Media Lab, completed his Ph.D. in machine learning for real-time gesture recognition in 2011, and has published in top journals and conferences across machine learning and HCI, such as the Journal of Machine Learning Research, SIGGRAPH, UIST, CHI, and Nature.

Niels Plath is a senior advisor to Booster. His published MJFF scientific biography describes neurodegeneration drug discovery and MunaCSO service, with prior Lundbeck globalresearch/neuroscience leadership and FreieUniversitätBerlin postdoctoral neuronal-plasticity research. Outsidecareer titles are source-dated background, not appointments atBooster.

Nigel Reuel serves as a BigHat Biosciences advisor.

Pascale Fung is a member of the founding team at AMI Labs, which researches world models for AI systems that understand and act in the physical world.

Biotechnology investor and company builder with previous investing experience at Omega Funds and Polaris Partners and neuroscience training.

Philip Van Damme is a QurAlis clinical adviser and neurologist at KU Leuven investigating ALS and neuromuscular disorders. His career includes doctoral training in Leuven and visiting research at Massachusetts General Hospital.

Biopharmaceutical investor and biotechnology researcher formerly with Jeito Capital, Smart Immune and Institut Imagine.

Product executive with former roles at Lightning AI, Confluent and VMware; leads Archetype AI’s enterprise product strategy.

Biopharma investor previously with Bain Capital Life Sciences, trained in stem-cell biology and epigenetics.

Saining Xie is a member of the founding team at AMI Labs, which researches world models for AI systems that understand and act in the physical world.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads. The company’s December 2023 profile identified Hu as Head of Biology with experience in antibody drug discovery and oncology research.

Stanley Lapidus serves as a BigHat Biosciences advisor.

Life-sciences transactions lawyer with experience at Sanofi, Fresenius Medical Care and Foley Hoag.

Steve Doberstein serves as a BigHat Biosciences advisor.

Theresa Tribble serves as a BigHat Biosciences advisor.

Also published as Zhaoyuan Chen in Phrontline’s Chinese announcement and scientific publications; develops antibody-drug conjugate technologies and leads Phrontline Biopharma.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads.

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads. The company’s December 2023 profile identified Mao as Head of Chemistry, specializing in medicinal chemistry and linker-payload design.

Yann LeCun is a Frontier AI Partner at 224 Ventures, participating in sourcing, evaluation and voting on investments. The firm’s launch identifies him as executive chairman of Advanced Machine Intelligence, an NYU professor and a Turing Award co-winner.

Aaron Solomon is listed by BigHat Biosciences as Associate Director, Computational Platform.

Abiy Seifu is listed by BigHat Biosciences as Sr. Software Engineer II.

Adam Carr is listed by BigHat Biosciences as Associate Director, Cell-Free Production.

Albert Misko is published by Arbor Biotechnologies as Vice President, Head of Clinical Development.

Andy Conrad serves as a BigHat Biosciences board member.

Anisha Keshavan is listed by BigHat Biosciences as Principal Data Scientist.

Annalisa Sharkey is listed by BigHat Biosciences as Product Manager II.

Anthony Cadena is listed by BigHat Biosciences as Associate Director, Discovery Medicine.

Barbara Steurer is listed by BigHat Biosciences as Sr. Scientist I, Target Biology.

Brendan Mullaney is listed by BigHat Biosciences as Sr. Director, Scientific Software Product.

Brett Weinstein is listed by BigHat Biosciences as VP, Finance.

Britt Adamson is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Assistant Professor of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics, Princeton University.

Caleb Ling is listed by BigHat Biosciences as Sr. Research Associate.

Cameron Corday is listed by BigHat Biosciences as Associate Scientist.

Charbel Eid is listed by BigHat Biosciences as VP, Platform.

Chris Malcuit is published by Arbor Biotechnologies as Senior Vice President, Technical Operations.

Crystal Humphries is listed by BigHat Biosciences as Principal Data Scientist.

Dan Anderson is listed by BigHat Biosciences as Senior Software Engineer II.

Danielle Barreras is listed by BigHat Biosciences as Associate Scientist.

David Scott is published by Arbor Biotechnologies as Co-Founder. Arbor lists this professional background: Co-Founder and CEO, Instance.

David Walt is published by Arbor Biotechnologies as Co-Founder and Board Member. Arbor lists this professional background: Arbor Co-Founder; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School. IlluminaVentures currentownpublished affiliation: Advisor. David is the Hansjörg Wyss Professor of Bioinspired Engineering and a professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital, as well as a core faculty member of the Wyss Institute at Harvard University. Additionally, David is an associate member at the Broad Institute, Howard Hughes Medical Institute professor, and co-director of the Mass General Brigham Center for COVID Innovation. David pioneered the use of microwell arrays for single-molecule detection and genetic measurements, which has revolutionized the process of genetic and proteomic analysis, enabling the cost of DNA sequencing and genotyping to plummet nearly a millionfold in the last decade. He is the scientific founder of Illumina and Quanterix Corp. David also co-founded multiple life science startups, including Ultivue, Arbor Biotechnologies, Sherlock Biosciences, Vizgen and Torus Biosciences. His lab develops new diagnostics tools and new biomarker assay technologies based on single molecule detection that can address unmet clinical needs in diagnostics. The lab focuses on early detection of breast cancer, active tuberculosis, and other infectious diseases and diagnosis of neurodegenerative diseases. His lab has also helped develop new tools to understand and diagnose COVID-19 and pursues fundamental research on single enzyme molecules to provide insight into enzyme mechanisms. David has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules. In 2025, David was awarded the National Medal of Technology and Innovation, bestowed by the president of the United States on individuals who have made exemplary achievements in science, technology, and innovation to strengthen the nation’s well-being. In addition, he was awarded the 2021 Kabiller Prize in Nanoscience and Nanomedicine. He is a member of the National Academy of Engineering and the National Academy of Medicine. David is a Fellow of the American Academy of Arts and Sciences, the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science, and the National Academy of Inventors, where he was inducted into its Hall of Fame. David received a Bachelor of Science in Chemistry from the University of Michigan and a PhD in Chemical Biology from SUNY at Stony Brook in New York. Portfolio involvement is institutionalboard/support context, not personalcash attribution.

Devin Junkins is listed by BigHat Biosciences as Sr. Automation Engineer I.

Devyn Smith is published by Arbor Biotechnologies as Chief Executive Officer and Board Member. Arbor lists this professional background: Chief Executive Officer.

Diana David is listed by BigHat Biosciences as Sr. Executive Administrator.

Don Haut is published by Arbor Biotechnologies as Chief Business Officer.

Duc Huynh is listed by BigHat Biosciences as Sr. Scientist I, Translational Research.

Eddie Abrams is listed by BigHat Biosciences as Chief Information Officer.

Elisabeth Visser is listed by BigHat Biosciences as Sr. Research Associate.

Eman Khan is listed by BigHat Biosciences as Senior Research Associate.

Emily Delaney is listed by BigHat Biosciences as Associate Director, External Programs.

Emily Sever is listed by BigHat Biosciences as Scientist I.

Emma Scaff is listed by BigHat Biosciences as Research Associate I.

Eva Boettcher is listed by BigHat Biosciences as Associate Scientist.

Evelyn Alferez is listed by BigHat Biosciences as Research Associate II, CFPS Production.

Feng Zhang is published by Arbor Biotechnologies as Co-Founder. Arbor lists this professional background: Core Institute Member, Broad Institute of MIT and Harvard.

Guangping Gao is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Co-Director, Li Weibo Institute for Rare Disease Research; Director, Horae Gene Therapy Center and Viral Vector Core; Professor of Microbiology and Physiological Systems; Penelope Booth Rockwell Professor in Biomedical Research, University of Massachusetts Medical School.

Helena Fu is listed by BigHat Biosciences as Associate Scientist.

Hunter Elliott is listed by BigHat Biosciences as VP, Machine Learning.

Ing Ongpipattanakul is listed by BigHat Biosciences as Scientist II, External Programs.

Ira Magaziner is published by Arbor Biotechnologies as Board Member. Arbor lists this professional background: President, SJS Inc..

Isabella Bangs is listed by BigHat Biosciences as Assistant Lab Manager.

Iya Kessler is published by Arbor Biotechnologies as General Counsel and Corporate Secretary.

Jeremy Hert is listed by BigHat Biosciences as Director, Engineering.

John Corbin is listed by BigHat Biosciences as Chief Development Officer.

Jon Wojciak is listed by BigHat Biosciences as Sr. Director, Preclinical Development.

Jordan Sullivan is listed by BigHat Biosciences as Associate Director, Production and Reagents.

Julie Zorn is listed by BigHat Biosciences as Senior Director, Antibody Engineering.

Katrina Stephenson is listed by BigHat Biosciences as Sr. Scientist I.

Keith Cheah is listed by BigHat Biosciences as Senior Data Scientist I.

Keltoum Boukra is listed by BigHat Biosciences as Principal Automation Engineer.

Kevin Alexander is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Assistant Professor of Medicine - Cardiovascular Medicine, Stanford University School of Medicine.

Le Cong is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Assistant Professor of Pathology and Genetics, Stanford University.

Lee Ann Marchionna is published by Arbor Biotechnologies as Chief People Officer.

Lindsey Osimiri is listed by BigHat Biosciences as Sr. Manager, Data Science.

Liz Schwarzbach is listed by BigHat Biosciences as Chief Business Officer.

Malin Parmar serves on Arbor Biotechnologies’ scientific advisory board. She leads developmental and regenerative neurobiology research at Lund University. Arbor spells her surname Parmer; the matching Lund University profile confirms Parmar.

Mark Angelino is published by Arbor Biotechnologies as Board Member. Arbor lists this professional background: Venture Partner, Third Rock Ventures.

Marleny Ramos is listed by BigHat Biosciences as Lab Operations Associate.

Mat Lindenmayer is published by Arbor Biotechnologies as Senior Vice President, Finance.

Mat Pletcher is published by Arbor Biotechnologies as Chief Scientific Officer.

Meirong Gao is listed by BigHat Biosciences as Senior Scientist, Display Technologies.

Melanie Montgomery is listed by BigHat Biosciences as Sr. Scientist II.

Michael Yessaillian is listed by BigHat Biosciences as Sr. Software Engineer I.

Michelle Gaus is listed by BigHat Biosciences as Associate Director, People Operations.

Mira Markova is listed by BigHat Biosciences as Senior Scientist I, Cell Line Engineering.

Mitchell Stieg is listed by BigHat Biosciences as Sr. Automation Engineer II.

Monique Merchant is listed by BigHat Biosciences as Scientist II, Discovery Medicine.

Nicholas Bhattacharya is listed by BigHat Biosciences as Machine Learning Scientist II.

Nithin Reddy is listed by BigHat Biosciences as Director, Engineering.

Noelle Huskey is listed by BigHat Biosciences as Director, Discovery Medicine.

Nolan Townsend is published by Arbor Biotechnologies as Board Member. Arbor lists this professional background: Chief Executive Officer, LEXEO Therapeutics.

Omar Nayfeh is listed by BigHat Biosciences as Research Associate II.

Osamu Nureki is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Professor, Dept of Biophysics and Biochemistry, Dept of Biological Sciences, Graduate School of Science, University of Tokyo School of Science.

Paavan Bhavsar is listed by BigHat Biosciences as Principal Software Engineer, Data Ops.

Patrick Hsu is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Assistant Professor and Deb Faculty Fellow, University of California, Berkeley.

Paul Meister is published by Arbor Biotechnologies as Chairman of the Board. Arbor lists this professional background: Chairman of the Board; Co-Founder, Liberty Lane Partners.

Peyton Greenside serves as a BigHat Biosciences chief executive officer, co-founder and board member.

Phil Maffettone is listed by BigHat Biosciences as Sr Machine Learning Scientist II.

Raaid Arshad is listed by BigHat Biosciences as Sr. Software Engineer II.

Raheel Ata is listed by BigHat Biosciences as Senior Director, Partnering and Strategy.

Rob Chess serves as a BigHat Biosciences board member.

Ryan Henrici is listed by BigHat Biosciences as VP, Discovery Medicine.

Sangeetha Iyer is listed by BigHat Biosciences as Director, Alliance Management.

Sayantan Mitra is listed by BigHat Biosciences as Director, Protein Sciences.

Sebastian Ober is listed by BigHat Biosciences as Sr Machine Learning Scientist II.

Shelby Joe is listed by BigHat Biosciences as Scientist I, Discovery Medicine.

Sichen Liang is listed by BigHat Biosciences as Associate Scientist.

Snigdha Agarwal is listed by BigHat Biosciences as Software Engineer II.

Stefan Weigand is listed by BigHat Biosciences as Chief Scientific Officer.

Stephen Goff is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Higgins Professor of Microbiology & Immunology and Biochemistry & Molecular Biophysics, Columbia University.